Birsen Dogu, Nezir Yılmaz, Sabriye Ozcekic and Hafize Oksuz. Late Onset Ornithine Transcarbamylase Deficiency Accompanying Severe HyperammonemiaAfter Cesarean Section: Case Report.
. 2015; 3(5):133-136. doi: 10.12691/AJMCR-3-5-4
ornithine carbamoyltransferase deficiency, urea cycle disorders, hyperammonemia, hemodialysis
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | Brusilow SW, Maestri NE. “Urea cycle disorders: diagnosis, pathophysiology, and therapy”. Adv Pediatr ; 43. 127-70. 1996. |
|
[2] | B.C. Lanpher, A. Gropman, K. A. Chapman, U. Lichter-Konecki,Urea CycleDisorders Consortium, andM. L. Summar, “Urea cycle disorders overview,” in GeneReviews [Internet], R.A.Pagon, T. D. Bird, C. R. Dolan, K. Stephens, and M. P. Adam, Eds., University of Washington, Seattle, Seattle, Wash, USA, 1993-2003. |
|
[3] | Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000; 105: e10. |
|
[4] | Kang ES, Snodgrass PJ, Gerald PS. “Ornithine transcarbamylase deficiency in the newborn infant”. J Pediatr. 82(4): 642-9, Apr.1973. |
|
[5] | McCullough BA, Yudkoff M, Batshaw ML, Wilson JM, Raper SE, Tuchman M. “Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype”. Am J Med Genet. 93(4). 313-9. Aug.2000. |
|
[6] | Tuchman M, McCullough BA, Yudkoff M. “The molecular basis of ornithine transcarbamylase deficiency”. Eur J Pediatr. 159(Suppl 3). S196-8. Dec.2000. |
|
[7] | Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Allewell NM. “The biochemical and molecular spectrum of ornithine transcarbamylase deficiency”. J Inherit Metab Dis. 21(Suppl 1): 40-58. 1998 |
|
[8] | Gordon N. “Ornithine transcarbamylase deficiency: a urea cycle defect” Eur J Paediatr Neurol. 7(3). 115-21. 2003. |
|
[9] | Ellaway CJ, Bennetts B, Tuck RR, Wilcken B. “Clumsiness, confusion,coma, and valproate”. Lancet. 353(9162). 1408. Apr24.1999. |
|
[10] | Choi D.E, Lee K.W, Shin Y.T, and Na KR, “Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency,”Journal of Korean Medical Science. 27(5). 556-9. May.2012. |
|
[11] | Diaz G.A, Krivitzky L.S, Mokhtarani M. et al., “Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate,” Hepatology. 57(6), 2171-9. Jun.2013. |
|
[12] | Maillot F and Crenn P. “Urea cycle disorders in adult patients,”Revue Neurologique, 163(10). 897-903. Oct.2007. |
|
[13] | Magoulas PL and El-Hattab AW, “Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management,” Orphanet Journal of Rare Diseases. 7. 68. Sep 18.2012. |
|
[14] | Mock CM and Schwetschenau KH, “Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy,” Am J Health Syst Pharm., 69(1).35-9. Jan1.2012. |
|
[15] | Mathias RS, Kostiner D, Packman S. “Hyperammonemia in urea cycle disorders: role of the nephrologist.” Am J Kidney Dis. 37(5). 1069-80. May. 2001. |
|
[16] | Wiegand C, Thompson T, Bock GH, Mathis RK, Kjellstrand CM, Mauer SM. “The management of life-threatening hyperammonemia: a comparison of several therapeutic modalities”. J Pediatr. 96(1). 142-4. Jan.1980. |
|